Melphalan, antimelanoma immunity, and inflammation-response

Cancer Research

Volumn 75, Issue 24, 2015, Pages 5400-5401

  Garg, Abhishek D ^a   Dudek Peric, Aleksandra M ^a   Agostinis, Patrizia ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 8; MELPHALAN; RANTES; ALKYLATING AGENT; CALRETICULIN; MEMBRANE ANTIGEN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; PHYSIOLOGY; SKIN TUMOR;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, ALKYLATING; CALRETICULIN; HUMANS; MELANOMA; MELPHALAN; SKIN NEOPLASMS;

EID: 84955518419     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2061     Document Type: Letter

References (5)

1. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res 2015;75:1603-14.
2. Martner A, Johansson J, Ben-Shabat I, Bagge RO. Melphalan, anti-melanoma immunity and inflammation - Letter. Cancer Res 2015;75:5398-9.
3. Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014;3: e968434.
4. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26.
5. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014;3:e955691.